Form 4: Fairmount Funds Management LLC, Kiselak and Harwin Report Stock Option Grants in Apogee Therapeutics

Fairmount Funds Management LLC, along with Tomas Kiselak and Peter Harwin, reported the acquisition of stock options in Apogee Therapeutics, Inc.

Summary

• Fairmount Funds Management LLC, Tomas Kiselak, and Peter Harwin filed a Form 4 detailing changes in beneficial ownership of Apogee Therapeutics, Inc. securities.
• The report indicates the acquisition of stock options, each representing the right to purchase 10,370 shares of Apogee's common stock at an exercise price of $43.85.
• The options vest on the one-year anniversary of the grant date (June 5, 2024), contingent upon continued service to Apogee.
• Kiselak and Harwin hold these options on behalf of Fairmount Funds, and any proceeds from the options will be turned over to Fairmount.
• Fairmount disclaims beneficial ownership except to the extent of its pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing related to stock option grants, which is a common practice. There's no explicit positive or negative information about the company's performance.

Positives

• The acquisition of stock options by directors and related entities can be seen as a sign of confidence in the company's future prospects.

Risks

• The vesting of the options is contingent upon continued service, which introduces a risk of forfeiture if service is terminated.

Future Outlook

The document does not contain specific forward-looking statements about Apogee Therapeutics' future performance, but the granting of stock options suggests an expectation of future value creation.

Management Comments

• Fairmount may be deemed a director by deputization of Issuer by virtue of the fact that each of Peter Harwin and Tomas Kiselak serve on the board of directors of Issuer and are also each a Managing Member of Fairmount.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel and align their interests with those of shareholders. This filing reflects standard compensation practices.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry, often vesting over a period of several years to incentivize long-term performance.
• The exercise price of $43.85 would need to be compared to the current market price of Apogee Therapeutics' stock to assess the immediate value of the options.
• Similar grants at comparable companies like BioNTech or Moderna often involve vesting schedules tied to specific milestones or performance metrics.

Stakeholder Impact

• The stock option grants could potentially dilute existing shareholders if the options are exercised.
• The grants incentivize the directors to work towards increasing shareholder value.

Key Dates